Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant

Giacomo, Costantino De; Flocca, R.; Villani, Laura; Licardi, G; Scotta, M. S.; Solcia, Enrico

doi:10.1016/s0022-3476(05)80152-0

Cited by 34 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They are treated, particularly in severe forms, with H2-receptor blockers, such as ranitidine, but in some patients, these drugs are of limited efficacy and agents such as omeprazole are needed. However, in children, the data available on the use of omeprazole, in all cases given orally, are limited [13,14,15,16]. Because the intravenous route is essential in patients unable to take oral medications, this study was undertaken in paediatric patients with medical indications for intravenous omeprazole in order to define the pharmacokinetics and metabolism of the drug.…”

mentioning

confidence: 99%

Pharmacokinetics of intravenous omeprazole in children

Jacqz-Aigrain

André

Bellaich

et al. 1994

Eur J Clin Pharmacol

View full text Add to dashboard Cite

This study was undertaken to define the pharmacokinetics of omeprazole in children and included 13 patients, heterogeneous in terms of age (0.3 to 19 years), underlying disease and biological constants, indication of omeprazole administration and associated therapy. The dose administered ranged from 36.9 to 139 mg.1.73 m-2. The pharmacokinetic parameters of omeprazole were: systemic clearance, 0.23 l.kg-1.h-1; volume of distribution, 0.45 l.kg-1; elimination half life 0.86 h; but were highly variable between individuals. Dosage, differences in hepatic and renal function and associated therapy may contribute to inter-individual variability. Within the range of doses administered, the pharmacokinetic parameters were similar to those reported in adults. The drug has been well tolerated in all children.

show abstract

mentioning

confidence: 99%

Pharmacokinetics of intravenous omeprazole in children

Jacqz-Aigrain

André

Bellaich

et al. 1994

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…23,24 São rapidamente absorvidos, altamente ligados às proteínas e geralmente bem tolerados, mas de modo semelhante a alguns bloqueadores H 2 , interagem com algumas enzimas microssomais do citocromo P450, podendo reduzir o catabolismo alguns fármacos, como varfarina e fenitoína. 25,11 Uma vez que causam inibição profunda e duradoura da secreção ácida gástrica, teoricamente é possível que possam interferir na absorção de fármacos em que o pH gástrico seja um fator importante para a biodisponibilidade (p. ex.…”

Section: Farmacocinéticaunclassified

“…A utilização em longo prazo de omeprazol em humanos pode possivelmente produzir proliferação de células e tumores carcinóides, porém não foram ainda claramente estabelecidos como uma conseqüência do uso crônico do medicamento. 25 A administração de pantoprazol em longo prazo (24 meses) em animais (ratos e camundongos) causou a inibição da secreção ácida gástrica, levando a hipergastrinemia, resultando na hiperplasia das células e observandose tumores carcinóides do estômago e cólon nos animais testados. Estes fenômenos não foram constatados em seres humanos.…”

Section: Efeitos Adversosunclassified

<b> INIBIDORES DA BOMBA DE PRÓTONS: REVISÃO E ANÁLISE FARMACOECONÔMICA </b>

2012

View full text Add to dashboard Cite

RESUMO:Os inibidores da bomba de prótons (IBPs), são medicamentos que inibem a enzima H + , K + ATPase (ou bomba de prótons) realizando a supressão ácida gástrica. Atualmente, são comercializados seis representantes desta classe: omeprazol, lansoprazol, pantoprazol, rabeprazol, esomeprazol e dexlansoprazol. Um novo IBP, tenatoprazol, está ainda em fase de desenvolvimento. O presente estudo propõese a revisar os estudos disponíveis a fim de expor informações sobre os IBPs e realizar um estudo farmacoeconômico entre dosespadrão desses medicamentos para o tratamento da úlcera péptica gastroduodenal. Evidências atuais sugerem que os IBPs possuem eficácia semelhante no tratamento de várias desordens gástricas e no protocolo de erradicação do Helicobacter pylori. A partir da análise farmacoeconômica ora realizada, constatouse que o lansoprazol apresenta perfil mais favorável.Descritores: Inibidores da bomba de prótons, Estudo farmacoeconômico. Proton Pump Inhibitors: Review and Analysis PharmacoeconomicABSTRACT: The proton pump inhibitors (PPIs) are drugs that inhibit the enzyme H+, K+ATPase (or proton pump), by performing gastric acid suppression. Currently, there are five marketed drugs of this class: omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole. A new PPI, tenatoprazole, is still under development. This study aims to review the available studies in order to reveal information about the PPIs and to perform a pharmacoeconomic study between standard doses of these drugs, employed in the treatment of gastroduodenal peptic ulcer. Current evidence suggests that PPIs have similar efficacy in the treatment of various gastric disorders and in the eradication of Helicobacter pylori. Through the pharmacoeconomic analysis done, it was found that lansoprazole presents a more favorable profile.Descriptors: Proton pump inhibitors; Pharmacoeconomic study.

show abstract

“…26 It has been documented in infants and children, and may respond to surgical antrectomy 26,29 ; one infant with severe peptic disease responded to omeprazole therapy. 30 Systemic mastocytosis, a disease in which mast cells accumulate in the skin, bone marrow, liver, spleen and gastrointestinal tract, is associated with acid hypersecretion. Eighty per cent of adult patients had gastrointestinal symptoms such as abdominal pain and diarrhoea; dyspeptic symptoms often were associated with duodenal erosion or ulcers.…”

Section: Hypersecretory Statesmentioning

confidence: 99%